Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Janssen Biotech, Inc. v. Celltrion Healthcare Co., Ltd. et al
Case Number:
1:16-cv-11117
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
July 31, 2018
Janssen Loses Remicade Patent Case To Pfizer, Celltrion
A recipe related to Janssen Biotech Inc.'s blockbuster immunosuppressant Remicade was too obvious for any competitor to have legally infringed a patent on it, a Massachusetts federal judge ruled Tuesday, allowing Pfizer Inc. to rest easy about the validity of its new-to-market equivalent to treat arthritis and psoriasis among other common conditions.
-
March 03, 2017
Judge Lays Out BPCIA 'Patent Dance' Rules
Biosimilar makers must satisfy each step of the Biologics Price Competition and Innovation Act's "patent dance" if they hope to reduce damages that innovator companies can seek for infringement, a Massachusetts federal judge said in a newly released opinion.
-
March 01, 2017
Biosimilar Talks Needed To Trigger Litigation Clock: Judge
A Massachusetts federal judge has ruled that biosimilar makers must engage in good-faith talks with innovator counterparts in order to trigger a litigation deadline for innovators to seek lost profits, according to representatives of Janssen Biotech and Pfizer.
-
June 17, 2016
Janssen Wants To Combine Celltrion Biosimilar Patent Suits
Janssen Biotech Inc. on Thursday asked a Massachusetts federal court to combine two patent cases it's bringing against Celltrion Healthcare Co. and Hospira Inc. over Inflectra, the defendants' biosimilar of Janssen's blockbuster immunosuppressant Remicade.